3[3]HEINO STASS.Pharmacokinetics,safety and tolerability of moxifloxacin.Clin Pharmacokinet,2001,40 (Suppl 1):1-9.
二级参考文献16
1Patrick P, Pierre A. Oral moxifloxacin vs high-doseage amoxicillin in the treatment of mild-to-moderate, communityacquired, suspected pneumococcal pneumonia in adults. Chest Vol Jan, 2001;119:185～195.
2Hoeffken G, Meyer HP. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med, 2001;95:553～564.
3Dean H, Timothy B. Short-course(5-day)moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Therapeutic Trent ,2001;19:117～136.
4Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest, 117,2000(Suppl.2): 380S～385S.
5Anthonisen NR, Manfreda J, Warren CPW, et al.: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med,2001 ;106: 192～204.
6Garcia-Rodriguez J A, Trujillano I, Fresnadillo M J, et al. In: Adam D, Finch R, eds. Moxifloxacin in practice. Maxim Medical, Oxford.1999:37～48.
8Souli M,Wennersten CB,Eliopoulous GM.In vitro activity of BAY 128039, a new fluoroquinolone, against species representative of respiratory tract pathogens[].International Journal of Antimicrobial Agents.1998
9Bradford WZ,Daley CL.Multiple drug-resistant tuberculosis[].Infectious Diseases in Clinical Practice.1998
10Aldridge KE,Ashcraft DS.Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes[].Antimicrobial Agents and Chemotherapy.1997
3Chodosh S.DeAbate CA.Haverstock D,et al.Short-cours moxifloxacin therapy for treatment of acutr bacterical exacerbation of chronic bronehitis[J].Respir Med,2000,94(1):17.
4Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections[J].International Journal of Antimicrobial Agents,2001,(04):331341.
5Mblondeau J. The role of PK/PD parameters to avoid selection and increase of resistance.Mutant prevention concentration[J].Journal of Chemotherapy,2004.1-4.
6Chodosh S,DeAbate CA,Haverstock D. Short-cours moxi-floxacin therapy for treatment of acute bacterical exacerbation of chronic bronehitis[J].Respiratory Medicine,2000,(01):17.
7Zhou B,Jiang X,Zhai L. Moxifloxacin in the treatment of acute bacterial rhinosinusitis:results of a multicenter non-interventional study[J].Acta Oto-Laryngologica,2010,(09):1058-1064.
8Iakovlev VP,Polushkina NR.Moxifloxacin antimicrobial activity and pharmacokinetic properties[].Antibiotics and Chemotherapy.2010
9Baudouin S V.The pulmonary physician in critical care 3:criticalcare management of community acquired pneumonia[].Thorax.2011
